Identification of Prognosis-Associated Biomarkers in Thyroid Carcinoma by a Bioinformatics Analysis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Randle RW, Bushman NM, Orne J, et al. Papillary thyroid cancer: the good and bad of the “good cancer”. Thyroid. 2017;27:902–907. doi:10.1089/thy.2016.0632
   PubMed Web of Science ®Google Scholar
• Shobab L, Gomes-Lima C, Zeymo A, et al. Clinical, pathological, and molecular profiling of radioactive iodine refractory differentiated thyroid cancer. Thyroid. 2019;29:1262–1268. doi:10.1089/thy.2019.0075
   PubMed Web of Science ®Google Scholar
• Sun J, Shi R, Zhao S, et al. E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle. J Exp Clin Cancer Res. 2017;36:40. doi:10.1186/s13046-017-0504-6
   PubMed Web of Science ®Google Scholar
• Aytekin T, Aytekin A, Maralcan G, et al. A cyclin D1 (CCND1) gene polymorphism contributes to susceptibility to papillary thyroid cancer in the Turkish population. Asian Pac J Cancer Prev. 2014;15:7181–7185. doi:10.7314/APJCP.2014.15.17.7181
   PubMedGoogle Scholar
• Zhang K, Liu J, Li C, Peng X, Li H, Li Z. Identification and validation of potential target genes in papillary thyroid cancer. Eur J Pharmacol. 2019;843:217–225. doi:10.1016/j.ejphar.2018.11.026
   PubMed Web of Science ®Google Scholar
• Ma X, Pietsch J, Wehland M, et al. Differential gene expression profile and altered cytokine secretion of thyroid cancer cells in space. FASEB J. 2014;28:813–835. doi:10.1096/fj.13-243287
   PubMed Web of Science ®Google Scholar
• Oh JM, Baek SH, Gangadaran P, et al. A novel tyrosine kinase inhibitor can augment radioactive iodine uptake through endogenous sodium/iodide symporter expression in anaplastic thyroid cancer. Thyroid. 2020;30:501–518. doi:10.1089/thy.2018.0626
   PubMed Web of Science ®Google Scholar
• Kim SY, Kim SM, Chang HJ, et al. SoLAT (sorafenib lenvatinib alternating treatment): a new treatment protocol with alternating sorafenib and lenvatinib for refractory thyroid cancer. BMC Cancer. 2018;18:956. doi:10.1186/s12885-018-4854-z
   PubMed Web of Science ®Google Scholar
• Liu L, Li D, Chen Z, et al. Wild-type P53 induces sodium/iodide symporter expression allowing radioiodide therapy in anaplastic thyroid cancer. Cell Physiol Biochem. 2017;43:905–914. doi:10.1159/000481640
   PubMedGoogle Scholar
• Messina RL, Sanfilippo M, Vella V, et al. Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. Int J Cancer. 2012;130:2259–2270. doi:10.1002/ijc.26228
   PubMed Web of Science ®Google Scholar
• Bohinc B, Michelotti G, Diehl AM. Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway. Thyroid. 2013;23:1119–1126. doi:10.1089/thy.2012.0474
   PubMed Web of Science ®Google Scholar
• Xu X, Ding H, Rao G, et al. Activation of the Sonic Hedgehog pathway in thyroid neoplasms and its potential role in tumor cell proliferation. Endocr Relat Cancer. 2012;19:167–179. doi:10.1530/ERC-11-0305
   PubMed Web of Science ®Google Scholar
• Chen L, Yue J, Han X, Li J, Hu Y. Ouabain rescues rat nephrogenesis during intrauterine growth restriction by regulating the complement and coagulation cascades and calcium signaling pathway. J Dev Orig Health Dis. 2016;7:91–101. doi:10.1017/S2040174415007242
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen M, Zhao Y, et al. Complement and coagulation cascades pathway correlates with chemosensitivity and overall survival in patients with soft tissue sarcoma. Eur J Pharmacol. 2020;879:173121. doi:10.1016/j.ejphar.2020.173121
   PubMed Web of Science ®Google Scholar
• Castiblanco-Valencia MM, Fraga TR, Pagotto AH, et al. Plasmin cleaves fibrinogen and the human complement proteins C3b and C5 in the presence of Leptospira interrogans proteins: a new role of LigA and LigB in invasion and complement immune evasion. Immunobiology. 2016;221:679–689. doi:10.1016/j.imbio.2016.01.001
   PubMed Web of Science ®Google Scholar
• Jeon S, Kim Y, Jeong YM, Bae JS, Jung CK. CCND1 splice variant as a novel diagnostic and predictive biomarker for thyroid cancer. Cancers. 2018;10:437. doi:10.3390/cancers10110437
   PubMed Web of Science ®Google Scholar
• Sanjari M, Kordestani Z, Safavi M, Mashrouteh M, FekriSoofiAbadi M, Ghaseminejad Tafreshi A. Enhanced expression of Cyclin D1 and C-myc, a prognostic factor and possible mechanism for recurrence of papillary thyroid carcinoma. Sci Rep. 2020;10:5100. doi:10.1038/s41598-020-61985-1
   PubMed Web of Science ®Google Scholar
• Bommarito A, Richiusa P, Carissimi E, et al. BRAFV600E mutation, TIMP-1 upregulation, and NF-kappaB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr Relat Cancer. 2011;18:669–685. doi:10.1530/ERC-11-0076
   PubMed Web of Science ®Google Scholar
• Liu H, Deng H, Zhao Y, Li C, Liang Y. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. J Exp Clin Cancer Res. 2018;37(1):279. doi:10.1186/s13046-018-0950-9
   PubMed Web of Science ®Google Scholar
• Gui X, Li Y, Zhang X, Su K, Cao W. Circ_LDLR promoted the development of papillary thyroid carcinoma via regulating miR-195-5p/LIPH axis. Cancer Cell Int. 2020;20:241. doi:10.1186/s12935-020-01327-3
   PubMed Web of Science ®Google Scholar
• Qin A, Liu Q, Wang J. Ropivacaine inhibits proliferation, invasion, migration and promotes apoptosis of papillary thyroid cancer cells via regulating ITGA2 expression. Drug Dev Res. 2020;81:700–707. doi:10.1002/ddr.21671
   PubMed Web of Science ®Google Scholar
• Liu H, Chen X, Lin T, Chen X, Yan J, Jiang S. MicroRNA-524-5p suppresses the progression of papillary thyroid carcinoma cells via targeting on FOXE1 and ITGA3 in cell autophagy and cycling pathways. J Cell Physiol. 2019;234:18382–18391. doi:10.1002/jcp.28472
   PubMed Web of Science ®Google Scholar
• Li J, Vasilyeva E, Wiseman SM. Beyond immunohistochemistry and immunocytochemistry: a current perspective on galectin-3 and thyroid cancer. Expert Rev Anticancer Ther. 2019;19:1017–1027. doi:10.1080/14737140.2019.1693270
   PubMed Web of Science ®Google Scholar
• Zhang WQ, Sun W, Qin Y, et al. Knockdown of KDM1A suppresses tumour migration and invasion by epigenetically regulating the TIMP1/MMP9 pathway in papillary thyroid cancer. J Cell Mol Med. 2019;23(8):4933–4944. doi:10.1111/jcmm.14311
   PubMed Web of Science ®Google Scholar